Cargando…

Higher lung deposition with Respimat(®) Soft Mist(™) Inhaler than HFA-MDI in COPD patients with poor technique

Aerosols delivered by Respimat(®) Soft Mist(™) Inhaler (SMI) are slower-moving and longer-lasting than those from pressurized metered-dose inhalers (pMDIs), improving the efficiency of pulmonary drug delivery to patients. In this four-way cross-over study, adults with chronic obstructive pulmonary d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brand, Peter, Hederer, Bettina, Austen, George, Dewberry, Helen, Meyer, Thomas
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2008
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2650591/ https://www.ncbi.nlm.nih.gov/pubmed/19281091

Ejemplares similares

Use of Respimat(®) Soft Mist™ Inhaler in COPD patients
por: Anderson, Paula
Publicado: (2006)

Asthma patients prefer Respimat(®) Soft Mist™ Inhaler to Turbuhaler(®)
por: Hodder, Rick, et al.
Publicado: (2009)

Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat(®) Soft Mist™ Inhaler in COPD
por: Hodder, Rick, et al.
Publicado: (2011)

The Respimat(®) Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients
por: Iwanaga, Takashi, et al.
Publicado: (2019)

Development of Respimat(®) Soft Mist™ Inhaler and its clinical utility in respiratory disorders
por: Dalby, Richard N, et al.
Publicado: (2011)

Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat(®) Soft Mist(™) Inhaler
por: Hodder, Richard, et al.
Publicado: (2009)

Reduced Environmental Impact of the Reusable Respimat(®) Soft Mist™ Inhaler Compared with Pressurised Metered-Dose Inhalers
por: Hänsel, Michaela, et al.
Publicado: (2019)

A dose-ranging study of tiotropium delivered via Respimat(®) Soft Mist(TM) Inhaler or HandiHaler(®) in COPD patients
por: Caillaud, Denis, et al.
Publicado: (2007)

Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function
por: Kunz, Christina, et al.
Publicado: (2016)

Long-term safety of tiotropium delivered by Respimat(®) SoftMist™ Inhaler: patient selection and special considerations
por: Tan, Ching Kuo, et al.
Publicado: (2016)

A Handling Study to Assess Use of the Respimat(®) Soft Mist™ Inhaler in Children Under 5 Years Old
por: Kamin, Wolfgang, et al.
Publicado: (2015)

Efficiency of Ipratropium Bromide and Albuterol Deposition in the Lung Delivered via a Soft Mist Inhaler or Chlorofluorocarbon Metered‐Dose Inhaler
por: MacGregor, TR, et al.
Publicado: (2016)

Patient perceptions of the re-usable Respimat(®) Soft Mist™ inhaler in current users and those switching to the device: A real-world, non-interventional COPD study
por: Dreher, Michael, et al.
Publicado: (2021)

Development of Room Temperature Stable Formulation of Formoterol Fumarate/Beclomethasone HFA pMDI
por: Purohit, D., et al.
Publicado: (2009)

In vitro dose comparison of Respimat(®) inhaler with dry powder inhalers for COPD maintenance therapy
por: Ciciliani, Anna-Maria, et al.
Publicado: (2017)

Inhaler usability of a pressurized metered dose inhaler and a soft mist inhaler in patients with COPD: A simulated-use study
por: Ding, Bo, et al.
Publicado: (2018)

Pharmacokinetics and tolerability (Study 1) with particular reference to ocular safety (Study 2) of tiotropium Respimat(®) Soft Mist(™) Inhaler: findings from two dose-ranging studies in healthy men
por: Feifel, Ulrich, et al.
Publicado: (2008)

Reducing carbon footprint by switching to reusable soft-mist inhalers
por: Janson, Christer, et al.
Publicado: (2023)

Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat(®) or HandiHaler(®)
por: Dekhuijzen, Pieter Nicolaas Richard, et al.
Publicado: (2016)

Assessment of inhalation flow patterns of soft mist inhaler co-prescribed with dry powder inhaler using inspiratory flow meter for multi inhalation devices
por: Hira, Daiki, et al.
Publicado: (2018)

TRONARTO: A Randomized, Placebo-Controlled Study of Tiotropium/Olodaterol Delivered via Soft Mist Inhaler in COPD Patients Stratified by Peak Inspiratory Flow
por: Mahler, Donald A, et al.
Publicado: (2021)

Water Uptake by Evaporating pMDI Aerosol Prior to Inhalation Affects Both Regional and Total Deposition in the Respiratory System
por: Legh-Land, Victoria, et al.
Publicado: (2021)

Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis
por: Halpin, David MG, et al.
Publicado: (2015)

Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD
por: Fabbri, Leonardo M., et al.
Publicado: (2016)

The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies
por: Ichinose, Masakazu, et al.
Publicado: (2016)

Device use errors with soft mist inhalers: A global systematic literature review and meta-analysis
por: Navaie, Maryam, et al.
Publicado: (2020)

Efficacy and safety of tiotropium Respimat(®) SMI in COPD in two 1-year randomized studies
por: Bateman, Eric, et al.
Publicado: (2010)

Technical Evaluation of Soft Mist Inhaler Use in Patients with Chronic Obstructive Pulmonary Disease: A Cross-Sectional Study
por: Zhang, Wei, et al.
Publicado: (2020)

Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study
por: Ferguson, Gary T., et al.
Publicado: (2018)

Effect of MDI Actuation Timing on Inhalation Dosimetry in a Human Respiratory Tract Model
por: Talaat, Mohamed, et al.
Publicado: (2022)

Prognostic Impact of the HFA-PEFF Score in Patients with Acute Myocardial Infarction and an Intermediate to High HFA-PEFF Score
por: Lee, Kwan Yong, et al.
Publicado: (2022)

CLIC MDI Overview
por: Gatignon, Lau
Publicado: (2012)

CLIC MDI Overview
por: Gatignon, Lau
Publicado: (2012)

Pharmacokinetic Study of Epinephrine Hydrofluoroalkane (Primatene MIST) Metered-Dose Inhaler
por: Kerwin, Edward M., et al.
Publicado: (2020)

Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD
por: Chen, Rongchang, et al.
Publicado: (2020)

Effectiveness of one-on-one coaching in improving pressurized metered dose inhaler (pMDI) technique among COPD patients: a prospective clinical study
por: Kim, Jin Sun, et al.
Publicado: (2021)

A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids
por: Vogelberg, Christian, et al.
Publicado: (2015)

Incorporating the Environmental Impact into a Budget Impact Analysis: The Example of Adopting RESPIMAT(®) Re-usable Inhaler
por: Ortsäter, Gustaf, et al.
Publicado: (2019)

MDI or nebulization in moderate to severe COVID-19 disease with COPD: which one is better?
por: Chilkoti, Geetanjali T., et al.
Publicado: (2021)

Clinical effectiveness of the Respimat(®) inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices
por: Ram, Felix SF, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_78l3vatdnrc7k8ln1h1ldcr3e6